AOBiome

AOBiome Featured in Dermatology Times

Positive Phase 2b Results Unveiled in Atopic Dermatitis, Pruritus Treatment B244 demonstrated significant levels of efficacy in patients with mild-to-severe atopic dermatitis and itch.

AOBiome announces the publication of positive Phase 2b results in The Lancet’s eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus.

https://www.aobiome.com/pressreleases/aobiome-announces-the-publication-of-positive-phase-2b-results-in-the-lancets-eclinicalmedicine-for-b244-in-the-treatment-of-mild-to-moderate-atopic-dermatitis-and-moderate-to-severe-pruritus/

AOBiome announces the publication of positive Phase 2b results in The Lancet's eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus - AOBiome AOBiome announces the publication of positive Phase 2b results in The Lancet’s eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus. The peer-reviewed publication describes the significant effects of B244 in 4 weeks across key endpoints ...